ADMP

Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

Retrieved on: 
Thursday, September 7, 2023
Human, Emergency, OUD, Doctor of Philosophy, DMK, ADMP, Pain, Incidence, MD, Patient, SAN, CUSIP, Fentanyl, Substance abuse, Pharmaceutical industry, Adamis

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders.

Key Points: 
  • SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders.
  • In conjunction with the name change, the company’s common stock is expected to trade under the new Nasdaq ticker symbol “DMK” on or about September 8, 2023.
  • Along with our flagship approved treatment for emergency treatment of opioid overdose, ZIMHI, our lead clinical stage compound, DPI-125 will be our core focus.
  • There can be no assurances that any of these milestones will be achieved or will be achieved within the anticipated time periods.

Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 21, 2023
NIAAA, House, White House, National Institute on Alcohol Abuse and Alcoholism, Senate, SG, Naloxone, Oklahoma Department of Mental Health and Substance Abuse Services, Opioid use disorder, Mental health, Office of National Drug Control Policy, Research, Doctor of Philosophy, DMK, ADMP, Sale, US, MD, Representative, SAN, United States Domestic Policy Council, R, Neuro, NIH, Pharmaceutical industry, Alcoholism, Adamis

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Revenues for the second quarter ending June 30, 2023 were $0.0 million compared to $0.0 million for the same period in 2022.
  • Revenues were negligible in both periods because no manufacturing of commercial products occurred in the second quarter in 2023 or 2022.
  • Research and development (R&D) expense for the second quarter of 2023 was $0.4 million compared to $3.2 million in the second quarter of the prior year.

Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering

Retrieved on: 
Friday, August 4, 2023
Park Avenue, SEC filing, ADMP, Sale, Register, Prospectus, SAN, Form, Security (finance), Registration statement

Each unit was sold at a public offering price of $1.35.

Key Points: 
  • Each unit was sold at a public offering price of $1.35.
  • The common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance.
  • Gross proceeds, before deducting placement agent fees and other offering expenses, were approximately $8.0 million.
  • The offering was made only by means of a prospectus which is a part of the Registration Statement.

Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

Retrieved on: 
Wednesday, August 2, 2023
Park Avenue, SEC filing, ADMP, Sale, Register, Prospectus, SAN, Form, Security (finance), Registration statement

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit.

Key Points: 
  • SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit.
  • Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $8.0 million.
  • The offering is expected to close on August 4, 2023, subject to the satisfaction of customary closing conditions.
  • The offering is being made only by means of a prospectus which is a part of the Registration Statement.

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

Retrieved on: 
Friday, July 28, 2023
Xylazine, University, Naloxone, Leiden University Medical Center, Tennessee Bureau of Investigation, Opioid overdose, Research, Doctor of Philosophy, ADMP, Parent, Trial of the century, Incidence, MD, Drug, Poisoning, Hypoventilation, Patient, Hearing, SAN, FDA, LUMC, Regulation of tobacco by the U.S. Food and Drug Administration, Fentanyl, Food, Anesthesiology, Pharmaceutical industry, Anesthesia, Adamis

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.

Key Points: 
  • SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation ( NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
  • The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University.
  • Dr. Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses.
  • Samuel P. Chapman, Director of Parents for Safer Children, stated, “Prescription strength ZIMHI is the best remedy available for opioid overdose.

Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder

Retrieved on: 
Monday, June 26, 2023
National Institute on Alcohol Abuse and Alcoholism, Physician, Research, Doctor of Philosophy, Bangladesh Technical Education Board, ADMP, Government, AUD, MD, Patient, Social isolation, SAN, SUD, NIH, NIAAA, Addiction, Pharmaceutical industry, Alcoholism

Different types of drug addiction fall under the umbrella term of substance use disorders or SUD.

Key Points: 
  • Different types of drug addiction fall under the umbrella term of substance use disorders or SUD.
  • We had previously stated our goal was to continue getting non-dilutive funding from the government and this funding from NIAAA clearly helps to further this goal.
  • AUD affected 29.5 million Americans over the age of 12 in 20213 and co-use of alcohol continues to be associated with opioid overdose deaths.
  • Adamis recognizes the urgent, unmet need to address the paucity of therapeutic options for patients dealing with AUD.

Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention

Retrieved on: 
Thursday, June 22, 2023
House, Joe Biden 2020 presidential campaign, White House, September 11, University, Senate, Prevalence, Naloxone, Office of National Drug Control Policy, Tennessee Bureau of Investigation, Oklahoma Department of Mental Health and Substance Abuse Services, Health, Mental health, Fentanyl, ONDCP, Opioid overdose, Research, Federal, Doctor of Philosophy, Adamis, ADMP, White, Plasma, Death, MD, Representative, Hypoventilation, SAN, United States Domestic Policy Council, Leiden University, FDA, Anesthesiology, Pharmaceutical industry, Medical device

Dr. Gupta is the first medical doctor to ever lead the White House Office of National Drug Control Policy (ONDCP).

Key Points: 
  • Dr. Gupta is the first medical doctor to ever lead the White House Office of National Drug Control Policy (ONDCP).
  • Adamis applauds the Administration’s Roundtable efforts in bringing together manufacturers of opioid reversal agents to reduce opioid induced deaths and is pleased and proud to work with the White House, ONDCP and Federal agencies to further opportunities for public private partnerships.
  • I believe it is essential to equip first responders with Adamis’ ZIMHI injectable naloxone product to deal with this alarming trend.
  • In explaining their findings, Dr. Dahan stated that, “An initial high blood concentration of naloxone is most effective in reversing a massive opioid overdose.

Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals

Retrieved on: 
Thursday, May 25, 2023
RSU, Opioid use disorder, OUD, Doctor of Philosophy, DMK, ADMP, Patient, SAN, Disease, Pharmaceutical industry, Adamis

The common stock of Adamis will continue to trade on the Nasdaq Capital Market under the ticker symbol “ADMP”.

Key Points: 
  • The common stock of Adamis will continue to trade on the Nasdaq Capital Market under the ticker symbol “ADMP”.
  • At the close of the merger, Ebrahim Versi, CEO of DMK, was named CEO of Adamis and Chairman of the Board of Directors.
  • Pursuant to the terms of the merger transaction, Adamis issued shares of common stock and Series E Convertible Preferred Stock to the former shareholders of DMK.
  • Adamis Chairman, Richard C. Williams, and Mr. Marguglio resigned their prior director roles in connection with the closing of the merger.

Adamis Pharmaceuticals Announces Reverse Stock Split

Retrieved on: 
Friday, May 19, 2023
Shareholder, Eastern Time Zone, Stock split, ADMP, SAN, Special, Nashville Charter Amendment 1, CUSIP, Security (finance)

SAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time.

Key Points: 
  • SAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time.
  • The reverse stock split is primarily intended to increase the market price per share of the Company’s common stock to regain compliance with the minimum bid price requirement for maintaining its listing on Nasdaq.
  • The reverse stock split is also a closing condition pursuant to the Company’s previously announced merger transaction with DMK Pharmaceuticals Corporation.
  • The new CUSIP number for the common stock following the reverse split will be 00547W 307.

Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 15, 2023
Allergy, Research, DMK, ADMP, Sale, SAN, Neuro, Pharmaceutical industry, Cryptocurrency, Security (finance), Adamis

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.
  • Total net revenue for the first quarter of 2023 was approximately $1.5 million compared to approximately $1.2 million in the first quarter of 2022, an increase of approximately 26%.
  • ET, during which Company executives will review financial information for the first quarter of 2023 and provide a corporate update, which may include an update concerning the results of the Company’s special meeting of stockholders held on May 15, 2023, as well as concerning the proposals acted upon at the meeting.
  • To listen to the replay please visit the events page of the Adamis investor relations section of the company website at http://ir.adamispharmaceuticals.com/events-presentations .